用于治疗肥胖症和2型糖尿病的新型GIPR拮抗剂
Novel GIPR Antagonists for Treating Obesity and Type 2 Diabetes Mellitus.
作者信息
Sabnis Ram W
机构信息
Smith, Gambrell & Russell LLP, 1105 W. Peachtree Street NE, Suite 1000, Atlanta, Georgia 30309, United States.
出版信息
ACS Med Chem Lett. 2024 Nov 14;15(12):2091-2092. doi: 10.1021/acsmedchemlett.4c00535. eCollection 2024 Dec 12.
Abstract
Provided herein are novel GIPR antagonists, pharmaceutical compositions, use of such compounds in treating obesity and type 2 diabetes mellitus and processes for preparing such compounds.
摘要
本文提供了新型GIPR拮抗剂、药物组合物、此类化合物在治疗肥胖症和2型糖尿病中的用途以及制备此类化合物的方法。
相似文献
1
Novel GIPR Antagonists for Treating Obesity and Type 2 Diabetes Mellitus.用于治疗肥胖症和2型糖尿病的新型GIPR拮抗剂
ACS Med Chem Lett. 2024 Nov 14;15(12):2091-2092. doi: 10.1021/acsmedchemlett.4c00535. eCollection 2024 Dec 12.
2
Novel Cyanopyridine Compounds as KHK Inhibitors for Treating NAFLD, NASH, and Type II Diabetes.新型氰基吡啶化合物作为治疗非酒精性脂肪性肝病、非酒精性脂肪性肝炎和II型糖尿病的KHK抑制剂
ACS Med Chem Lett. 2024 Jul 23;15(8):1191-1192. doi: 10.1021/acsmedchemlett.4c00332. eCollection 2024 Aug 8.
3
Novel Bicyclic Heterocycles as MRGPRX2 Antagonists for Treating Inflammatory Diseases.新型双环杂环化合物作为治疗炎症性疾病的MRGPRX2拮抗剂
ACS Med Chem Lett. 2025 Jun 2;16(6):980-981. doi: 10.1021/acsmedchemlett.5c00305. eCollection 2025 Jun 12.
4
Novel Glucagon-like Peptide 1 Receptor Agonists for Treating Type II Diabetes.用于治疗II型糖尿病的新型胰高血糖素样肽1受体激动剂
ACS Med Chem Lett. 2024 Jul 11;15(8):1182-1183. doi: 10.1021/acsmedchemlett.4c00303. eCollection 2024 Aug 8.
5
Novel Ergoline Compounds as 5-HT2A Agonists for Treating Mood Disorders Such as Depressive Disorders and Bipolar Disorders.新型麦角灵化合物作为5-HT2A激动剂用于治疗情绪障碍，如抑郁症和双相情感障碍。
ACS Med Chem Lett. 2024 Dec 20;16(1):32-33. doi: 10.1021/acsmedchemlett.4c00593. eCollection 2025 Jan 9.
6
Novel 3-Pyrrolidineindole Derivatives as Serotonergic Psychedelic Agents for Treating Psychosis and Mental Illnesses Such as Depression and Post-Traumatic Stress Disorder.新型3-吡咯烷吲哚衍生物作为5-羟色胺能致幻剂用于治疗精神病以及抑郁症和创伤后应激障碍等精神疾病。
ACS Med Chem Lett. 2024 Dec 10;16(1):18-19. doi: 10.1021/acsmedchemlett.4c00581. eCollection 2025 Jan 9.
7
Novel TYK2 Inhibitors for Treating Autoimmune and Inflammatory Diseases.用于治疗自身免疫性和炎性疾病的新型酪氨酸激酶2（TYK2）抑制剂
ACS Med Chem Lett. 2024 Dec 9;16(1):8-9. doi: 10.1021/acsmedchemlett.4c00566. eCollection 2025 Jan 9.
8
Novel Aryl Hydrocarbon Receptor Agonist Compounds for Treating Psoriasis and Atopic Dermatitis.用于治疗银屑病和特应性皮炎的新型芳烃受体激动剂化合物
ACS Med Chem Lett. 2025 May 16;16(6):935-936. doi: 10.1021/acsmedchemlett.5c00267. eCollection 2025 Jun 12.
9
MALT1 Inhibitors for Treating Cancer and Immunological Diseases.用于治疗癌症和免疫疾病的MALT1抑制剂
ACS Med Chem Lett. 2024 Aug 20;15(9):1419-1420. doi: 10.1021/acsmedchemlett.4c00390. eCollection 2024 Sep 12.
10
Novel AHR Agonists for Treating Psoriasis and Atopic Dermatitis.用于治疗银屑病和特应性皮炎的新型芳烃受体激动剂。
ACS Med Chem Lett. 2024 Jun 21;15(7):996-997. doi: 10.1021/acsmedchemlett.4c00262. eCollection 2024 Jul 11.
本文引用的文献
1
Insights into the structure and activation mechanism of some class B1 GPCR family members.一些 B1 类 G 蛋白偶联受体家族成员的结构和激活机制的研究进展。
Mol Biol Rep. 2024 Sep 6;51(1):966. doi: 10.1007/s11033-024-09876-w.
2
Targeting the incretin system in obesity and type 2 diabetes mellitus.针对肥胖症和 2 型糖尿病的肠促胰岛素系统。
Nat Rev Endocrinol. 2024 Aug;20(8):447-459. doi: 10.1038/s41574-024-00979-9. Epub 2024 Apr 17.
3
Targeting the GLP-2 receptor in the management of obesity.针对肥胖症管理中的 GLP-2 受体。
Peptides. 2024 Jul;177:171210. doi: 10.1016/j.peptides.2024.171210. Epub 2024 Apr 3.
Zotero 插件